MET and renal cell carcinoma: While no specific FDA-approved therapies for TFE3-rearranged RCC are formulated, its molecular features suggest potential benefits from MET or VEGF pathway inhibitors, while immunotherapy with immune checkpoint inhibitors is also an alternative.